Agex Therapeutics Stock Shares Owned By Institutions
| AGEDelisted Stock | USD 0.74 0.01 1.37% |
AgeX Therapeutics fundamentals help investors to digest information that contributes to AgeX Therapeutics' financial success or failures. It also enables traders to predict the movement of AgeX Stock. The fundamental analysis module provides a way to measure AgeX Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AgeX Therapeutics stock.
AgeX |
AgeX Therapeutics Company Shares Owned By Institutions Analysis
AgeX Therapeutics' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current AgeX Therapeutics Shares Owned By Institutions | 5.64 % |
Most of AgeX Therapeutics' fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AgeX Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
CompetitionBased on the latest financial disclosure, 5.64% of AgeX Therapeutics are shares owned by institutions. This is 87.37% lower than that of the Biotechnology sector and 88.13% lower than that of the Health Care industry. The shares owned by institutions for all United States stocks is 85.62% higher than that of the company.
AgeX Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AgeX Therapeutics' direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AgeX Therapeutics could also be used in its relative valuation, which is a method of valuing AgeX Therapeutics by comparing valuation metrics of similar companies.AgeX Therapeutics is currently under evaluation in shares owned by institutions category among its peers.
AgeX Fundamentals
| Return On Asset | -0.82 | |||
| Operating Margin | (63.57) % | |||
| Current Valuation | 33.33 M | |||
| Shares Outstanding | 2.5 M | |||
| Shares Owned By Insiders | 75.73 % | |||
| Shares Owned By Institutions | 5.64 % | |||
| Number Of Shares Shorted | 4.47 K | |||
| Price To Earning | (5.95) X | |||
| Price To Book | 12.96 X | |||
| Price To Sales | 221.90 X | |||
| Revenue | 142 K | |||
| Gross Profit | 125 K | |||
| EBITDA | (9.83 M) | |||
| Net Income | (14.8 M) | |||
| Cash And Equivalents | 645 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 4.37 M | |||
| Debt To Equity | 0.75 % | |||
| Current Ratio | 0.19 X | |||
| Book Value Per Share | 5.07 X | |||
| Cash Flow From Operations | (7.8 M) | |||
| Short Ratio | 3.88 X | |||
| Earnings Per Share | (13.36) X | |||
| Beta | 1.19 | |||
| Market Capitalization | 31.51 M | |||
| Total Asset | 11.96 M | |||
| Retained Earnings | (131.01 M) | |||
| Working Capital | (5.16 M) | |||
| Current Asset | 5.06 M | |||
| Current Liabilities | 5.17 M | |||
| Z Score | -14.21 | |||
| Net Asset | 11.96 M |
About AgeX Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AgeX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AgeX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AgeX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in AgeX Stock
If you are still planning to invest in AgeX Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AgeX Therapeutics' history and understand the potential risks before investing.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |